Acadia Pharmaceuticals Inc (ACAD) 34.21 $ACAD
Acadia Pharmaceuticals Could Be The Most Sought After Company Of 2015
Investing Healthcare - at Seeking Alpha - Thu Feb 12, 8:40AM CST
ACAD: 34.21 (+0.37), AZN: 69.96 (+0.20), PDP: 42.52 (+0.28), ABBV: 58.05 (+1.00)
Will CVS Health's (CVS) Earnings Surprise this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 10:00AM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? is scheduled to report its fourth-quarter and full year 2014 results before the opening bell on Feb 10.
ACAD: 34.21 (+0.37), ACT: 285.37 (+3.71), DXCM: 62.68 (+0.74), CVS: 102.63 (-0.37)
Cushman & Wakefield: REITs Will Continue to Rock in 2015 – And Which Ones to Buy
at The Street - Fri Feb 06, 11:39AM CST
In 2014, REITs outperformed the stock market. Cushman & Wakefield investment sales chairman analyzes the market and offers REITs to watch in 2015.
GGP: 29.25 (-0.28), ACAD: 34.21 (+0.37), VNOD: 25.26 (-0.23), UDR: 32.45 (-0.22), KIM: 26.83 (-0.25), EQY: 26.97 (-0.23), BXP: 141.08 (-1.58), AVB: 170.82 (-2.57), ESRT: 18.03 (-0.22), SLG: 128.59 (-0.65), EQR: 78.75 (-1.11)
Dynavax Announces Laura Brege Has Joined Board of Directors and Denise Gilbert Will Retire
Marketwired - Fri Feb 06, 8:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Laura Brege to its Board of Directors and Audit Committee. Denise Gilbert, a director and the Chair of the Audit Committee since 2004, will retire from her positions with the company following the next Audit Committee meeting, whereupon Ms. Brege will become Chair of the Committee.
DVAX: 16.96 (+0.66), RRD-P.VN: 0.010 (+0.005), ACAD: 34.21 (+0.37), PETX: 16.52 (-0.10)
Myriad Genetics Q2 Earnings, Revenues Beat; Fall Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:58AM CST
Although Myriad's (MYGN) second-quarter fiscal 2015 results beat the Zacks Consensus Estimate on both the top and bottom line fronts, on a year-over-year basis, both the figures declined substantially.
ACAD: 34.21 (+0.37), MYGN: 34.03 (+0.40), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13)
An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Feb 01, 12:02PM CST
The market activity of billionaire investors tends to attract a lot of attention because these billionaires are often perceived as having some kind of special insight into the direction of the broader market or individual stocks. In the world of...
ACAD: 34.21 (+0.37), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68)
Qiagen (QGEN) Disappoints with Q4 Earnings, Revenue Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 1:20PM CST
Qiagen NV (QGEN), a provider of sample and assay technologies, posted a disappointing fourth-quarter 2014 with lower-than-expected earnings and revenues.
ACAD: 34.21 (+0.37), ALXN: 182.29 (+6.02), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
Uptrend Call Working As Acadia Pharmaceuticals Stock Rises 20.2% (ACAD)
Comtex SmarTrend(R) - Wed Jan 28, 11:15AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 3 months, Acadia Pharmaceuticals has returned 20.18% as of today's recent price of $31.59.
ACAD: 34.21 (+0.37)
Biotech Stocks Technical Report - Halozyme Therapeutics, Agenus, Biogen Idec, ACADIA Pharma, and Peregrine Pharma
PR Newswire - Wed Jan 28, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Agenus Inc. (NASDAQ: AGEN), Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research report on Halozyme Therapeutics can be accessed at http://get.Investor-Edge.com/pdf/?c=Halozyme%...amp;s=HALO. On Tuesday, January 27, 2015, the NASDAQ Composite ended at 4,681.50, down 1.89%, the Dow Jones Industrial Average declined 1.65%, to finish the day at 17,387.21, and the S&P 500 closed at 2,029.55, down 1.34%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 818.80, down 0.75%, while the index has advanced 8.40% in the previous three months. Register for your complimentary reports at the links given below.
AGEN: 5.03 (-0.01), BIIB: 391.66 (-0.45), ACAD: 34.21 (+0.37), HALO: 14.73 (+0.23), PPHM: 1.28 (+0.03)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)
25.3% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Wed Jan 21, 9:49AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 3 months, Acadia Pharmaceuticals has returned 25.28% as of today's recent price of $32.93.
ACAD: 34.21 (+0.37)
Acadia Pharmaceuticals Has Returned 29.1% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Jan 14, 9:12AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 3 months, Acadia Pharmaceuticals has returned 29.12% as of today's recent price of $33.94.
ACAD: 34.21 (+0.37)
After Yesterday's Rally of 2.68% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jan 09, 4:41PM CST
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $31.86 to a high of $33.73. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $32.62 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 34.21 (+0.37)
Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1
at The Street - Thu Jan 08, 12:09PM CST
The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.
OREX: 5.55 (+0.10), BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), ESRX: 84.90 (+0.40), ACAD: 34.21 (+0.37), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), NPSP: 45.88 (+0.03), SNY: 49.42 (+0.82), FOLD: 8.36 (-0.11), CELG: 115.88 (+0.16)
Acadia Pharmaceuticals Up 17.9% Since SmarTrend Uptrend Call (ACAD)
Comtex SmarTrend(R) - Tue Jan 06, 5:24PM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 3 months, Acadia Pharmaceuticals has returned 17.86% as of today's recent price of $30.98.
ACAD: 34.21 (+0.37)
ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
Business Wire - Tue Jan 06, 8:02AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015, at 11:30 a.m. Pacific Time in San Francisco.
ACAD: 34.21 (+0.37), JPM: 59.67 (+0.10)
Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)
at The Street - Wed Dec 24, 8:57AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate
ACAD: 34.21 (+0.37)
4 Reasons I'm Adding Gilead To My Healthcare Holdings
Brian Nichols - at Seeking Alpha - Wed Dec 24, 6:18AM CST
JNJ: 99.62 (+1.18), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), CLDX: 20.97 (+0.53)
ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
at The Street - Tue Dec 23, 11:40AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ACAD: 34.21 (+0.37)
Acadia Pharmaceuticals Could Be The Most Sought After Company Of 2015
Investing Healthcare - at Seeking Alpha - Thu Feb 12, 8:40AM CST
ACAD: 34.21 (+0.37), AZN: 69.96 (+0.20), PDP: 42.52 (+0.28), ABBV: 58.05 (+1.00)
Will CVS Health's (CVS) Earnings Surprise this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 10:00AM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? is scheduled to report its fourth-quarter and full year 2014 results before the opening bell on Feb 10.
ACAD: 34.21 (+0.37), ACT: 285.37 (+3.71), DXCM: 62.68 (+0.74), CVS: 102.63 (-0.37)
Cushman & Wakefield: REITs Will Continue to Rock in 2015 – And Which Ones to Buy
at The Street - Fri Feb 06, 11:39AM CST
In 2014, REITs outperformed the stock market. Cushman & Wakefield investment sales chairman analyzes the market and offers REITs to watch in 2015.
GGP: 29.25 (-0.28), ACAD: 34.21 (+0.37), VNOD: 25.26 (-0.23), UDR: 32.45 (-0.22), KIM: 26.83 (-0.25), EQY: 26.97 (-0.23), BXP: 141.08 (-1.58), AVB: 170.82 (-2.57), ESRT: 18.03 (-0.22), SLG: 128.59 (-0.65), EQR: 78.75 (-1.11)
Dynavax Announces Laura Brege Has Joined Board of Directors and Denise Gilbert Will Retire
Marketwired - Fri Feb 06, 8:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Laura Brege to its Board of Directors and Audit Committee. Denise Gilbert, a director and the Chair of the Audit Committee since 2004, will retire from her positions with the company following the next Audit Committee meeting, whereupon Ms. Brege will become Chair of the Committee.
DVAX: 16.96 (+0.66), RRD-P.VN: 0.010 (+0.005), ACAD: 34.21 (+0.37), PETX: 16.52 (-0.10)
Myriad Genetics Q2 Earnings, Revenues Beat; Fall Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:58AM CST
Although Myriad's (MYGN) second-quarter fiscal 2015 results beat the Zacks Consensus Estimate on both the top and bottom line fronts, on a year-over-year basis, both the figures declined substantially.
ACAD: 34.21 (+0.37), MYGN: 34.03 (+0.40), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13)
An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Feb 01, 12:02PM CST
The market activity of billionaire investors tends to attract a lot of attention because these billionaires are often perceived as having some kind of special insight into the direction of the broader market or individual stocks. In the world of...
ACAD: 34.21 (+0.37), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68)
Qiagen (QGEN) Disappoints with Q4 Earnings, Revenue Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 1:20PM CST
Qiagen NV (QGEN), a provider of sample and assay technologies, posted a disappointing fourth-quarter 2014 with lower-than-expected earnings and revenues.
ACAD: 34.21 (+0.37), ALXN: 182.29 (+6.02), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
Uptrend Call Working As Acadia Pharmaceuticals Stock Rises 20.2% (ACAD)
Comtex SmarTrend(R) - Wed Jan 28, 11:15AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 3 months, Acadia Pharmaceuticals has returned 20.18% as of today's recent price of $31.59.
ACAD: 34.21 (+0.37)
Biotech Stocks Technical Report - Halozyme Therapeutics, Agenus, Biogen Idec, ACADIA Pharma, and Peregrine Pharma
PR Newswire - Wed Jan 28, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Agenus Inc. (NASDAQ: AGEN), Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research report on Halozyme Therapeutics can be accessed at http://get.Investor-Edge.com/pdf/?c=Halozyme%...amp;s=HALO. On Tuesday, January 27, 2015, the NASDAQ Composite ended at 4,681.50, down 1.89%, the Dow Jones Industrial Average declined 1.65%, to finish the day at 17,387.21, and the S&P 500 closed at 2,029.55, down 1.34%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 818.80, down 0.75%, while the index has advanced 8.40% in the previous three months. Register for your complimentary reports at the links given below.
AGEN: 5.03 (-0.01), BIIB: 391.66 (-0.45), ACAD: 34.21 (+0.37), HALO: 14.73 (+0.23), PPHM: 1.28 (+0.03)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)
25.3% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Wed Jan 21, 9:49AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 3 months, Acadia Pharmaceuticals has returned 25.28% as of today's recent price of $32.93.
ACAD: 34.21 (+0.37)
Acadia Pharmaceuticals Has Returned 29.1% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Jan 14, 9:12AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 3 months, Acadia Pharmaceuticals has returned 29.12% as of today's recent price of $33.94.
ACAD: 34.21 (+0.37)
After Yesterday's Rally of 2.68% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jan 09, 4:41PM CST
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $31.86 to a high of $33.73. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $32.62 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 34.21 (+0.37)
Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1
at The Street - Thu Jan 08, 12:09PM CST
The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.
OREX: 5.55 (+0.10), BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), ESRX: 84.90 (+0.40), ACAD: 34.21 (+0.37), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), NPSP: 45.88 (+0.03), SNY: 49.42 (+0.82), FOLD: 8.36 (-0.11), CELG: 115.88 (+0.16)
Acadia Pharmaceuticals Up 17.9% Since SmarTrend Uptrend Call (ACAD)
Comtex SmarTrend(R) - Tue Jan 06, 5:24PM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 3 months, Acadia Pharmaceuticals has returned 17.86% as of today's recent price of $30.98.
ACAD: 34.21 (+0.37)
ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
Business Wire - Tue Jan 06, 8:02AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015, at 11:30 a.m. Pacific Time in San Francisco.
ACAD: 34.21 (+0.37), JPM: 59.67 (+0.10)
Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)
at The Street - Wed Dec 24, 8:57AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate
ACAD: 34.21 (+0.37)
4 Reasons I'm Adding Gilead To My Healthcare Holdings
Brian Nichols - at Seeking Alpha - Wed Dec 24, 6:18AM CST
JNJ: 99.62 (+1.18), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), CLDX: 20.97 (+0.53)
ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
at The Street - Tue Dec 23, 11:40AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ACAD: 34.21 (+0.37)
